Literature DB >> 16691621

Dedifferentiated central chondrosarcoma.

Eric L Staals1, Patrizia Bacchini, Franco Bertoni.   

Abstract

BACKGROUND: The prognosis for patients who develop dedifferentiation of central chondrosarcoma traditionally has been poor. Because not much has been reported about this rare lesion, many uncertainties remain about prognostic factors.
METHODS: In this retrospective study, the clinical, radiographic, and histologic features and the treatments in 123 patients from the Rizzoli Institute were reviewed in an attempt to define which factors may be related to outcome in patients with dedifferentiated central chondrosarcoma.
RESULTS: Among 123 patients who were included in this study, 109 patients were treated at the Rizzoli Institute, and 14 patients were seen in consultation. There were 66 males and 57 females, and their average age was 59 years. The femur (62 patients), pelvis (28 patients), and humerus (20 patients) were the most common locations. Radiographically, a soft tissue mass was present in 87% of patients, and a bimorphic pattern was appreciated in 53% of patients. Histologically, the cartilaginous component was considered Grade 1 in 63% of patients and Grade 2 in 37% of patients. In most patients, the dedifferentiated component showed the features of an osteosarcoma (92 patients), followed by fibrosarcoma (19 patients), and malignant fibrous histiocytoma (9 patients). For 101 patients, surgery was a component of their definitive management. In 25 patients, surgery was combined with chemotherapy. The 2-year and 5-year survival rates were 34% and 24%, respectively. The median survival was 13 months (95% confidence interval, 9-17 months).
CONCLUSIONS: Metastatic disease at diagnosis, malignant fibrous histiocytoma dedifferentiation, and a high percentage of dedifferentiated component were related to poorer outcomes. There was no statistical evidence of any beneficial effect from adjuvant chemotherapy. Copyright 2006 American Cancer Society.

Entities:  

Mesh:

Year:  2006        PMID: 16691621     DOI: 10.1002/cncr.21936

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  40 in total

Review 1.  Therapeutic molecular targets in human chondrosarcoma.

Authors:  Nuor Jamil; Sarah Howie; Donald M Salter
Journal:  Int J Exp Pathol       Date:  2010-10       Impact factor: 1.925

Review 2.  [Musculoskeletal tumors: significance of morphological diagnostics].

Authors:  M Werner; K Hauptmann; C H Lohmann; G Jundt
Journal:  Orthopade       Date:  2009-06       Impact factor: 1.087

3.  Establishment and characterization of a novel dedifferentiated chondrosarcoma cell line, NCC-dCS1-C1.

Authors:  Rieko Oyama; Fusako Kito; Mami Takahashi; Marimu Sakumoto; Kumiko Shiozawa; Zhiwei Qiao; Rei Noguchi; Takashi Kubo; Shunichi Toki; Fumihiko Nakatani; Akihiko Yoshida; Akira Kawai; Tadashi Kondo
Journal:  Hum Cell       Date:  2019-02-08       Impact factor: 4.174

Review 4.  The imaging of cartilaginous bone tumours. II. Chondrosarcoma.

Authors:  H Douis; A Saifuddin
Journal:  Skeletal Radiol       Date:  2012-10-04       Impact factor: 2.199

5.  The incidence of skip metastases on whole bone MRI in high-grade bone sarcomas.

Authors:  Asif Saifuddin; Ban Sharif; Ines Oliveira; Sarah Kalus; James Barnett; Ian Pressney
Journal:  Skeletal Radiol       Date:  2020-01-09       Impact factor: 2.199

6.  Extended intralesional treatment versus resection of low-grade chondrosarcomas.

Authors:  Chad Aarons; Benjamin K Potter; Sheila C Adams; J David Pitcher; H Thomas Temple
Journal:  Clin Orthop Relat Res       Date:  2009-01-14       Impact factor: 4.176

7.  Ezrin immunohistochemical expression in cartilaginous tumours: a useful tool for differential diagnosis between chondroblastic osteosarcoma and chondrosarcoma.

Authors:  Sébastien Salas; Gonzague de Pinieux; Anne Gomez-Brouchet; Frédérique Larrousserie; Xavier Leroy; Sébastien Aubert; Anne-Valérie Decouvelaere; Roch Giorgi; Carla Fernandez; Corinne Bouvier
Journal:  Virchows Arch       Date:  2008-12-03       Impact factor: 4.064

8.  Does ifosfamide therapy improve survival of patients with dedifferentiated chondrosarcoma?

Authors:  Satoshi Kawaguchi; Tao Sun; Patrick P Lin; Michael Deavers; Nusrat Harun; Valerae O Lewis
Journal:  Clin Orthop Relat Res       Date:  2013-11-07       Impact factor: 4.176

9.  Dedifferentiated chondrosarcoma: our clinico-pathological experience and dilemmas in 25 cases.

Authors:  Jelena Sopta; Aleksandar Dordević; Goran Tulić; Vesna Mijucić
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-25       Impact factor: 4.553

10.  Consequences and prevention of inadvertent internal fixation of primary osseous sarcomas.

Authors:  Sheila Conway Adams; Benjamin K Potter; Zakariah Mahmood; J David Pitcher; H Thomas Temple
Journal:  Clin Orthop Relat Res       Date:  2008-10-21       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.